Erik P. Castle, MD, argues that using high intensity focused ultrasound (HIFU) to treat prostate cancer, as the technology stands today, results in too many negative quality of life outcomes for patients. Therefore, HIFU is not ready to be a standard of care in urological practices.
Read More
Dr. Phillip J. Koo, MD, discusses the appropriate timing of radium 223 treatments in castration resistant prostate cancer patients, the best approaches to therapeutic layering, and the importance of recognizing bone metastasis when making these therapeutic decisions.
Read More
Alan H. Bryce, MD, argues that the urologic community should expand genetic testing in prostate cancer patients. With expansive, quality data, urologists will be able to better recognize aberrations in patients’ genes. Also, this would be a step closer to gaining FDA approved biomarkers for prostate cancer.
Read More
Dr. Robert Aboussaly, MD, explains up-to-date approaches to treating upper tract urothelial carcinoma, including risk-stratification in diagnosis, nephroureterectomy, neoadjuvant chemotherapy, post-operative intravesical chemotherapy, and more.
Read More
Dr. Ryan P. Terlecki, MD, FACS, explains why and how clinicians should not simply carry out therapies to prevent or arrest disease quickly. They should also aim to minimize possible late side effects, social hazards, and cost for their patients.
Read More